Literature DB >> 21368230

Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes.

Stephanie A McClymont1, Amy L Putnam, Michael R Lee, Jonathan H Esensten, Weihong Liu, Maigan A Hulme, Ulrich Hoffmüller, Udo Baron, Sven Olek, Jeffrey A Bluestone, Todd M Brusko.   

Abstract

Regulatory T cells (Tregs) constitute an attractive therapeutic target given their essential role in controlling autoimmunity. However, recent animal studies provide evidence for functional heterogeneity and lineage plasticity within the Treg compartment. To understand better the plasticity of human Tregs in the context of type 1 diabetes, we characterized an IFN-γ-competent subset of human CD4(+)CD127(lo/-)CD25(+) Tregs. We measured the frequency of Tregs in the peripheral blood of patients with type 1 diabetes by epigenetic analysis of the Treg-specific demethylated region (TSDR) and the frequency of the IFN-γ(+) subset by flow cytometry. Purified IFN-γ(+) Tregs were assessed for suppressive function, degree of TSDR demethylation, and expression of Treg lineage markers FOXP3 and Helios. The frequency of Tregs in peripheral blood was comparable but the FOXP3(+)IFN-γ(+) fraction was significantly increased in patients with type 1 diabetes compared to healthy controls. Purified IFN-γ(+) Tregs expressed FOXP3 and possessed suppressive activity but lacked Helios expression and were predominately methylated at the TSDR, characteristics of an adaptive Treg. Naive Tregs were capable of upregulating expression of Th1-associated T-bet, CXCR3, and IFN-γ in response to IL-12. Notably, naive, thymic-derived natural Tregs also demonstrated the capacity for Th1 differentiation without concomitant loss of Helios expression or TSDR demethylation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21368230      PMCID: PMC3091943          DOI: 10.4049/jimmunol.1003099

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

1.  Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype.

Authors:  Dat Q Tran; Heather Ramsey; Ethan M Shevach
Journal:  Blood       Date:  2007-07-20       Impact factor: 22.113

Review 2.  Treg in type 1 diabetes.

Authors:  Todd Brusko; Mark Atkinson
Journal:  Cell Biochem Biophys       Date:  2007       Impact factor: 2.194

3.  Inducible regulatory T cells (iTregs) from recent-onset type 1 diabetes subjects show increased in vitro suppression and higher ITCH levels compared with controls.

Authors:  Sanja Glisic; Sarah Ehlenbach; Parthav Jailwala; Jill Waukau; Srikanta Jana; Soumitra Ghosh
Journal:  Cell Tissue Res       Date:  2010-02-09       Impact factor: 5.249

4.  Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells.

Authors:  Angela M Thornton; Patricia E Korty; Dat Q Tran; Elizabeth A Wohlfert; Patrick E Murray; Yasmine Belkaid; Ethan M Shevach
Journal:  J Immunol       Date:  2010-02-24       Impact factor: 5.422

5.  Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells.

Authors:  Jun Wang; Andreea Ioan-Facsinay; Ellen I H van der Voort; Tom W J Huizinga; René E M Toes
Journal:  Eur J Immunol       Date:  2007-01       Impact factor: 5.532

6.  Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction.

Authors:  Qizhi Tang; Jason Y Adams; Cristina Penaranda; Kristin Melli; Eliane Piaggio; Evridiki Sgouroudis; Ciriaco A Piccirillo; Benoit L Salomon; Jeffrey A Bluestone
Journal:  Immunity       Date:  2008-05-08       Impact factor: 31.745

7.  DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells.

Authors:  Udo Baron; Stefan Floess; Georg Wieczorek; Katrin Baumann; Andreas Grützkau; Jun Dong; Andreas Thiel; Tina J Boeld; Petra Hoffmann; Matthias Edinger; Ivana Türbachova; Alf Hamann; Sven Olek; Jochen Huehn
Journal:  Eur J Immunol       Date:  2007-09       Impact factor: 5.532

8.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.

Authors:  Sarah E Allan; Sarah Q Crome; Natasha K Crellin; Laura Passerini; Theodore S Steiner; Rosa Bacchetta; Maria G Roncarolo; Megan K Levings
Journal:  Int Immunol       Date:  2007-02-27       Impact factor: 4.823

9.  Epigenetic control of the foxp3 locus in regulatory T cells.

Authors:  Stefan Floess; Jennifer Freyer; Christiane Siewert; Udo Baron; Sven Olek; Julia Polansky; Kerstin Schlawe; Hyun-Dong Chang; Tobias Bopp; Edgar Schmitt; Stefan Klein-Hessling; Edgar Serfling; Alf Hamann; Jochen Huehn
Journal:  PLoS Biol       Date:  2007-02       Impact factor: 8.029

10.  Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses.

Authors:  Ye Zheng; Ashutosh Chaudhry; Arnold Kas; Paul deRoos; Jeong M Kim; Tin-Tin Chu; Lynn Corcoran; Piper Treuting; Ulf Klein; Alexander Y Rudensky
Journal:  Nature       Date:  2009-02-01       Impact factor: 49.962

View more
  194 in total

Review 1.  CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.

Authors:  Qizhi Tang; Jeffrey A Bluestone; Sang-Mo Kang
Journal:  J Mol Cell Biol       Date:  2011-12-14       Impact factor: 6.216

2.  Oligodeoxynucleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion.

Authors:  Yong Chan Kim; Ravikiran Bhairavabhotla; Jeongheon Yoon; Amit Golding; Angela M Thornton; Dat Q Tran; Ethan M Shevach
Journal:  Blood       Date:  2012-01-31       Impact factor: 22.113

3.  Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells.

Authors:  Thomas Duhen; Rebekka Duhen; Antonio Lanzavecchia; Federica Sallusto; Daniel J Campbell
Journal:  Blood       Date:  2012-03-21       Impact factor: 22.113

Review 4.  Multiple sclerosis.

Authors:  Alyssa Nylander; David A Hafler
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 5.  Human lymphohematopoietic reconstitution and immune function in immunodeficient mice receiving cotransplantation of human thymic tissue and CD34(+) cells.

Authors:  Zheng Hu; Yong-Guang Yang
Journal:  Cell Mol Immunol       Date:  2012-02-06       Impact factor: 11.530

Review 6.  Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease.

Authors:  Michel DuPage; Jeffrey A Bluestone
Journal:  Nat Rev Immunol       Date:  2016-02-15       Impact factor: 53.106

Review 7.  The plasticity of human Treg and Th17 cells and its role in autoimmunity.

Authors:  Markus Kleinewietfeld; David A Hafler
Journal:  Semin Immunol       Date:  2013-11-05       Impact factor: 11.130

8.  Coexpression of TIGIT and FCRL3 identifies Helios+ human memory regulatory T cells.

Authors:  Khalid Bin Dhuban; Eva d'Hennezel; Emil Nashi; Amit Bar-Or; Sadiye Rieder; Ethan M Shevach; Satoshi Nagata; Ciriaco A Piccirillo
Journal:  J Immunol       Date:  2015-03-11       Impact factor: 5.422

9.  Th1/Th17 plasticity is a marker of advanced β cell autoimmunity and impaired glucose tolerance in humans.

Authors:  Linnea Reinert-Hartwall; Jarno Honkanen; Harri M Salo; Janne K Nieminen; Kristiina Luopajärvi; Taina Härkönen; Riitta Veijola; Olli Simell; Jorma Ilonen; Aleksandr Peet; Vallo Tillmann; Mikael Knip; Outi Vaarala
Journal:  J Immunol       Date:  2014-12-05       Impact factor: 5.422

Review 10.  Restoring Regulatory T Cells in Type 1 Diabetes.

Authors:  Allyson Spence; Qizhi Tang
Journal:  Curr Diab Rep       Date:  2016-11       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.